The potential role of naltrexone in borderline personality disorder
dc.contributor.author | Moghaddas, A | |
dc.contributor.author | Dianatkhah, M | |
dc.contributor.author | Ghaffari, S | |
dc.contributor.author | Ghaeli, P | |
dc.date.accessioned | 2018-08-26T09:41:04Z | |
dc.date.available | 2018-08-26T09:41:04Z | |
dc.date.issued | 2017 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58448 | |
dc.description.abstract | Objective: Management of borderline personality disorder (BPD) is a difficult challenge due to the complex features of this disorder. This article reviews the use of naltrexone in the treatment of BPD. Methods: Published articles and clinical trials were searched in Google Scholar, MedLine, ELSEVIER, and Cochrane database of systematic reviews abstracts in English language between 1990 and 2017. Results: Naltrexone (NTX), a nonspecific competitive opiate antagonist, has been noted to be helpful in controlling self-injurious behavior (SIB) and dissociative symptoms in patients with BPD. Conclusions: Further studies should be conducted on the effects of naltrexone to confirm the role of this medication in the treatment of BPD. | |
dc.language.iso | English | |
dc.relation.ispartof | Iranian Journal of Psychiatry | |
dc.subject | naltrexone | |
dc.subject | opiate antagonist | |
dc.subject | opiate receptor | |
dc.subject | Article | |
dc.subject | automutilation | |
dc.subject | borderline state | |
dc.subject | Cochrane Library | |
dc.subject | data base | |
dc.subject | decision making | |
dc.subject | dissociation | |
dc.subject | emotion | |
dc.subject | human | |
dc.subject | Medline | |
dc.subject | neuroendocrine system | |
dc.subject | psychiatry | |
dc.title | The potential role of naltrexone in borderline personality disorder | |
dc.type | Article | |
dc.citation.volume | 12 | |
dc.citation.issue | 2 | |
dc.citation.spage | 141 | |
dc.citation.epage | 146 | |
dc.citation.index | Scopus |